Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Sponsor
University Health Network, Toronto
Study ID
NCT02906943
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease. Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment. The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient. Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research. The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.

Key Dates

First listed
Sep 20, 2016
Start date
Aug 31, 2016
Status verified
Jun 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
10,000 participants (estimated)

Arms

  • Arm: Advanced cancer
    Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.

Primary Outcome Measure

Number of patients included in a province-wide registry of NGS panel-based testing results [ Time Frame: 5 years ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsColorectal cancer trialsHead and neck cancer trialsLung cancer trialsMelanoma trialsOncology trialsBreast oncology trialsWomen's health trialsGI oncology trialsENT trialsLung oncology trialsLung disease trialsSkin cancer trialsDermatology trials

Related Studies